Medical Facilities Corporation
TSX:DR.TOMedical - Care Facilities
+$0.18 today
- Market cap
- $282.59M
- Beta
- 0.34
- P/E (TTM)
- 8.7
- EPS (TTM)
- $1.47
- Dividend yield
- 2.00%
Volume 0.04M
Average 0.02M
DR.TO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Medical Facilities CorporationTSX: DR.TO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA declines year over year
Q1 FY2026 EBITDA of $15.06M fell 16.9% year over year, behind the -3.6% change in trailing-twelve-month EBITDA. Sequentially, it fell 27.6% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.
Context
- EBITDA amounted to 23.0% of revenue in FY2025, down 1.9 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $76.61M (+28.9%) for the fiscal year ending Dec 2026, a step up from the -28.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $15.06M-27.6% QoQ
- Last fiscal yearDec 2025
- $59.41M-28.1% YoY
- LTMMar 2026
- $75.52M-3.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -16.9% | -55.0% | -38.1 pp |
| 1 year | -28.1% | +28.9% | +57.0 pp |
| 3-year CAGR | +5.1% | +4.0% | -1.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 59.41M USD
- Year-over-year change
- -28.1%
- 4-year CAGR
- -12.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.41M | -28.1% |
| FY2024 | 2024-12-31 | 82.57M | +14.0% |
| FY2023 | 2023-12-31 | 72.43M | +41.6% |
| FY2022 | 2022-12-31 | 51.15M | -50.5% |
| FY2021 | 2021-12-31 | 103.4M | — |
EBITDA vs competitors
How DR.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.6% is the 7th highest of 9, against a peer median of +35.5%.
- EBITDA amounts to 24.7% of revenue for DR.TO, versus a peer median of 20.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $75.52M USD | -3.6% | +5.1% | 24.7% | |
| LTM Mar 2026 | $60.46M USD | +510.4% | — | 23.1% | |
| LTM Mar 2026 | CA$49.15M CAD | +45.8% | — | 31.0% | |
| LTM Mar 2026 | CA$30.12M CAD | +25.2% | — | 8.0% | |
| LTM Mar 2026 | -$5.36M USD | +48.2% | — | 10.5% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | -$36.45M USD | -1.4% | — | 194.3% |
| LTM Mar 2026 | -CA$40.84M CAD | -681.4% | — | 14.9% | |
| LTM Mar 2026 | -$44.63M USD | -141.2% | — | — | |
| LTM Mar 2026 | -CA$63.48M CAD | +86.8% | — | 20.4% | |
| Peer median (excluding DR.TO) | — | +35.5% | — | 20.4% | |
Competitors are the stored peer set for DR.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 398.63M | 424.55M | 445.58M | 331.53M | 258.62M |
| Cost of Revenue | 130.03M | 143.93M | 148.9M | 111.65M | 160.42M |
| Gross Profit | 268.61M | 280.63M | 296.68M | 219.88M | 98.2M |
| Gross Margin | 67.4% | 66.1% | 66.6% | 66.3% | 38.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 177.58M | 198.21M | 151.73M | 151.12M | 119.23M |
| Operating Expenses | 191.25M | 245.69M | 229.57M | 158.24M | 50.72M |
| Depreciation & Amortization | 26.77M | 20.76M | 21.54M | 19.37M | 11.94M |
| EBITDA | 103.4M | 51.15M | 72.43M | 82.57M | 59.41M |
| EBITDA Margin | 25.9% | 12.0% | 16.3% | 24.9% | 23.0% |
| Operating Income | 77.36M | 34.94M | 67.11M | 61.64M | 47.47M |
| Operating Margin | 19.4% | 8.2% | 15.1% | 18.6% | 18.4% |
| Interest Income | 76K | 8.54M | 717K | 1.87M | 2.24M |
| Interest Expense | 25.74M | 12.89M | 16.5M | 12.09M | 3.59M |
| Other Income / Expenses | (26.47M) | (17.44M) | (14.27M) | (10.53M) | (7.19M) |
| Income Before Tax | 50.89M | 17.5M | 52.32M | 51.11M | 40.28M |
| Pre-Tax Margin | 12.8% | 4.1% | 11.7% | 15.4% | 15.6% |
| Income Tax Expense | 4.4M | 5.21M | 8.33M | (5.69M) | 5.06M |
| Net Income | 15.5M | (4.41M) | 18.5M | 73.49M | 21.08M |
| Net Margin | 3.9% | -1.0% | 4.2% | 22.2% | 8.2% |
| EPS (Basic) | 1.50 | 0.42 | 0.73 | 1.03 | 1.09 |
| EPS (Diluted) | 1.49 | 0.42 | 0.73 | 1.03 | 1.09 |
| Weighted Avg Shares | 31.09M | 29.37M | 25.35M | 18.5M | 19.48M |
| Weighted Avg Shares (Diluted) | 31.13M | 29.37M | 25.25M | 24M | 19.48M |
Medical Facilities Corporation
TSX:DR.TO
Intrinsic Alpha fair value
Locked
Current Price
$17.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.